Literature DB >> 1974499

Hemodynamic differences between carvedilol and labetalol in the cutaneous circulation.

R R Ruffolo1, C F Sauermelch, R N Willette.   

Abstract

The effects of labetalol and carvedilol on local cutaneous microvascular perfusion and calculated local cutaneous microvascular resistance were investigated in anesthetized rats at submaximal doses that produced equivalent reductions in blood pressure and heart rate. Labetalol decreased cutaneous perfusion (-25% +/- 3%) without significantly affecting cutaneous vascular resistance (-6% +/- 3%). In marked contrast, carvedilol dramatically increased cutaneous perfusion (+64% +/- 9%) and significantly reduced cutaneous vascular resistance (-57% +/- 3%). These results suggest that carvedilol and labetalol possess differences in the mechanisms by which they produce vasodilation in vivo.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1974499     DOI: 10.1007/bf01409477

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  7 in total

1.  In vitro pharmacologic profile of the novel beta-adrenoceptor antagonist and vasodilator, carvedilol.

Authors:  A J Nichols; A C Sulpizio; D J Ashton; J P Hieble; R R Ruffolo
Journal:  Pharmacology       Date:  1989       Impact factor: 2.547

2.  Laser Doppler measurements of blood flow in skin tissue.

Authors:  D Boggett; J Blond; P Rolfe
Journal:  J Biomed Eng       Date:  1985-07

3.  Vascular effects of carvedilol, a new beta-adrenoceptor antagonist with vasodilating properties, in isolated canine coronary artery.

Authors:  Y Hattori; H Nakaya; M Endou; Y Nakao; M Kanno
Journal:  J Cardiovasc Pharmacol       Date:  1989-04       Impact factor: 3.105

4.  Studies on the mode of vasodilating action of carvedilol.

Authors:  G Sponer; K Strein; B Müller-Beckmann; W Bartsch
Journal:  J Cardiovasc Pharmacol       Date:  1987       Impact factor: 3.105

Review 5.  Antihypertensive compounds with combined actions.

Authors:  K H Rahn
Journal:  J Cardiovasc Pharmacol       Date:  1987       Impact factor: 3.105

Review 6.  A new molecule with vasodilating and beta-adrenoceptor blocking properties.

Authors:  U Abshagen
Journal:  J Cardiovasc Pharmacol       Date:  1987       Impact factor: 3.105

7.  Pharmacological profile of carvedilol as a beta-blocking agent with vasodilating and hypotensive properties.

Authors:  G Sponer; W Bartsch; K Strein; B Müller-Beckmann; E Böhm
Journal:  J Cardiovasc Pharmacol       Date:  1987-03       Impact factor: 3.105

  7 in total
  8 in total

1.  Long-term hemodynamic effects of antihypertensive treatment.

Authors:  P Lund-Johansen; P Omvik; J E Nordrehaug
Journal:  Clin Investig       Date:  1992

Review 2.  Carvedilol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders.

Authors:  C J Dunn; A P Lea; A J Wagstaff
Journal:  Drugs       Date:  1997-07       Impact factor: 9.546

Review 3.  Carvedilol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  D McTavish; D Campoli-Richards; E M Sorkin
Journal:  Drugs       Date:  1993-02       Impact factor: 9.546

Review 4.  Pharmacological profile of beta-adrenoceptor blockers with vasodilating properties, especially carvedilol--rationale for clinical use.

Authors:  G Sponer; W Bartsch; K Strein
Journal:  Clin Investig       Date:  1992

Review 5.  Carvedilol and the kidney.

Authors:  A G Dupont
Journal:  Clin Investig       Date:  1992

6.  Clinical pharmacology of carvedilol.

Authors:  B Tomlinson; B N Prichard; B R Graham; R J Walden
Journal:  Clin Investig       Date:  1992

Review 7.  A risk-benefit assessment of carvedilol in the treatment of cardiovascular disorders.

Authors:  W J Louis; H Krum; E L Conway
Journal:  Drug Saf       Date:  1994-08       Impact factor: 5.606

Review 8.  Clinical pharmacokinetics and pharmacodynamics of carvedilol.

Authors:  T Morgan
Journal:  Clin Pharmacokinet       Date:  1994-05       Impact factor: 6.447

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.